Response to Comments: MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease

This notice updates the LCD title to 'MolDX: Prostate Cancer Genomic Classifier Assay for Men with Localized Disease' and indicates the Decipher genomic classifier applies to men with localized prostate cancer. The provided excerpt contains no specific clinical coverage criteria, documentation requirements, limitations, or frequency limits — consult the full LCD L38303 for the definitive coverage policy.

"MolDX Prostate Cancer Genomic Classifier (Decipher) is intended for use in men with localized prostate cancer."

Sign up to see full coverage criteria, indications, and limitations.